QNCX Stock Analysis: Buy, Sell, or Hold?
QNCX - Quince Therapeutics, Inc. Common Stock
$0.16
0.08 (86.29%)
▲
5d:
+60.91%
30d:
+59.34%
90d:
-94.3%
WAIT
LOW Confidence
Analysis Updated: Apr 7, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When QNCX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: QNCX is 35.8% above fair value ($0.12). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: QNCX is 35.8% above fair value ($0.12). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: QNCX is currently trading at $0.16, which is considered extended relative to its 30-day fair value range of $0.09 to $0.12.
Technical Outlook: Technically, QNCX is in a strong downtrend. The price is approaching resistance at $0.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 86.3% recently.
Market Sentiment: QNCX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.00 (+2967.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QNCX is in a strong downtrend. The price is approaching resistance at $0.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 86.3% recently.
Market Sentiment: QNCX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.00 (+2967.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$0.09 -
$0.12
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+35.8% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+86.3%)
- BULLISH: Trading 2967.5% below Wall St target ($5.00)
- WARNING: Recommendation downgraded due to 35.8% overvaluation
Fair Price Analysis
30-Day Fair Range
$0.09 -
$0.12
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$0.08
Resistance Level
$0.11
Current Trend
Strong Downtrend
Technical data as of
Apr 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.14
Wall Street Target
$5.00
(+2967.5%)
Share & Embed Analysis
Last updated: April 08, 2026 7:03 AM ET
Data refreshes hourly during market hours. Next update: 8:03 AM
Data refreshes hourly during market hours. Next update: 8:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QNCX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 57 HOLD |
